首页 | 本学科首页   官方微博 | 高级检索  
     


Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58
Authors:Avivit Cahn MD  Stephen D. Wiviott MD  Ofri Mosenzon MD  Sabina A. Murphy MPH  Erica L. Goodrich MS  Ilan Yanuv MSc  Aliza Rozenberg MA  John P. H. Wilding MD  Lawrence A. Leiter MD  Deepak L. Bhatt MD  Darren K. McGuire MD  Leon Litwak MD  Adriaan Kooy MD  Ingrid A. M. Gause-Nilsson MD  Martin Fredriksson MD  Anna Maria Langkilde MD  Marc S. Sabatine MD  Itamar Raz MD
Affiliation:1. Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel;2. Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Womenʼs Hospital and Harvard Medical School, Boston, Massachusetts;3. Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK;4. Department of Medicine, Li Ka Shing Knowledge Institute, St. Michaelʼs Hospital, University of Toronto, Toronto, Canada;5. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas;6. Endocrinology Unit, Diabetes Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;7. University Medical Center Groningen and Bethesda Diabetes Research Center, Groningen, the Netherlands;8. BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Abstract:
Keywords:cardiovascular disease   dapagliflozin   GLP-1 analogue   heart failure   insulin therapy   metformin
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号